<DOC>
	<DOCNO>NCT01929213</DOCNO>
	<brief_summary>This study design investigate pharmacokinetic drug interaction safety oral administration Udenafil ( DA-8159 ) Bosentan healthy volunteer . Design : Randomized , open-label , multiple-dose , three-treatment , three-period , six-sequence , Williams design Investigational Product : Udenafil , Bosentan</brief_summary>
	<brief_title>Clinical Trial Investigate Pharmacokinetic Drug Interaction Between Udenafil Bosentan After Oral Administration</brief_title>
	<detailed_description />
	<mesh_term>Bosentan</mesh_term>
	<mesh_term>Udenafil</mesh_term>
	<criteria>healthy volunteer age 20 45 year old within range BMI 18.5 25 ( Body Mass Index ) neither congenital/chronic disease pathological symptoms/findings result medical examination doctor determine suitable subject within 4 week ago administration Hypersensitivity ( history hypersensitivity ) Udenafil , Bosentan PDE5 inhibitor Active Liver Diseases exceed 1.25 time normal range AST , ALT Gastrointestinal diseases surgery affect absorption drug Excessive drinking ( exceed 210g/week ) excessive caffeine ( exceed 5cups/day ) Smoking 10 cigarette per day pregnant nursing female volunteer</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>